Associated tags: Prostate cancer, Patient, Pharmaceutical industry, EPIX, SAN, ESSA, Conference, Webcast
Locations: NEW YORK, QUEBEC, BRITISH COLUMBIA, CALIFORNIA, CANADA
Retrieved on:
Thursday, October 28, 2021
Cancer,
EDGAR,
MCRPC,
Prostate,
Neoplasm,
AR,
Survival,
EPIX,
Twitter,
Fast Track,
Patient,
Private Securities Litigation Reform Act,
NASDAQ,
SEDAR,
FDA,
Health Canada,
Prostate cancer,
PCF,
Conference,
Adult,
Forward-looking statement,
Risk,
Company,
Man,
NTD,
IND,
Male,
Adenocarcinoma,
Testosterone,
N,
HIV disease progression rates,
AACR,
NMR,
Medical imaging,
Pharmaceutical industry Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.
Key Points:
- Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.
- The data were recently presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
- The Phase I clinical trial of EPI-7386 began in Q3 of 2020 following FDA allowance of the IND and Health Canada acceptance.
- Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth-most common cause of male cancer death worldwide (Globocan, 2018).
Nonsteroidal antiandrogens,
Chemistry,
Organic compounds,
Chemical compounds,
Prostate cancer,
Benzamides,
Nitriles,
Thioureas,
Enzalutamide,
Androgen receptor,
Antiandrogen,
EPI-7386 In the cellular model CWR-R1-AD1, driven by full-length AR, EPI-7386 inhibited the transcriptional activity of the AR similar to enzalutamide.
Key Points:
- In the cellular model CWR-R1-AD1, driven by full-length AR, EPI-7386 inhibited the transcriptional activity of the AR similar to enzalutamide.
- The AR-v567es splice variant is a clinically-detected AR splice variant that is constitutively active and is unresponsive to anti-androgens.
- Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018).
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Dr. Brettman is a Managing Director of Blackstone's Life Science Group and will be assuming more responsibilities in this role.
Key Points:
- Dr. Brettman is a Managing Director of Blackstone's Life Science Group and will be assuming more responsibilities in this role.
- "We are extremely grateful to Dr. Brettman for his strong leadership and valuable insights as a member of the Board of Directors," said Richard M. Glickman, Chairman of ESSA's Board of Directors.
- "It has been an honor to serve on ESSA's Board and witness the Company's tremendous growth over the past few years," said Dr. Brettman.
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients suffering from prostate cancer.
Retrieved on:
Thursday, February 25, 2021
Anatomy,
Branches of biology,
Organ systems,
Histopathology,
Prostate cancer,
Cancer,
Prostate,
MCRPC,
Survival rate,
Prostvac,
Management of prostate cancer ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Key Points:
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
- For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma .
- Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018).
- Despite these advances, many patients with mCRPC fail or develop resistance to existing treatments, leading to continued disease progression and limited survival rates.
Retrieved on:
Thursday, February 25, 2021
HOUSTON, Texas and VANCOUVER,Canada, Feb. 25, 2021 /PRNewswire/ -ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr.David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at three upcoming virtual investor conferences.
Key Points:
- HOUSTON, Texas and VANCOUVER,Canada, Feb. 25, 2021 /PRNewswire/ -ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr.David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at three upcoming virtual investor conferences.
- Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.
- Following the events, the webcasts will be archived on the ESSA website for 90 days.
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Retrieved on:
Thursday, February 25, 2021
We look forward to investigating the combination of these therapies and their potential role together in the treatment of prostate cancer."
Key Points:
- We look forward to investigating the combination of these therapies and their potential role together in the treatment of prostate cancer."
- The Phase I clinical trial of EPI-7386 began in Q3 of 2020 following FDA allowance of the IND and Health Canada acceptance.
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
- Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018).
Retrieved on:
Wednesday, January 13, 2021
Organic compounds,
Chemical compounds,
Organ systems,
Nonsteroidal antiandrogens,
Pyridines,
Progonadotropins,
Anti-acne preparations,
Apalutamide,
Antiandrogen,
Abiraterone acetate,
Prostate cancer,
EPI-7386 "We are delighted to collaborate with Janssen to explore the potential clinical role of EPI-7386 in combination with the antiandrogens apalutamide and abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer," said Dr. David.
Key Points:
- "We are delighted to collaborate with Janssen to explore the potential clinical role of EPI-7386 in combination with the antiandrogens apalutamide and abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer," said Dr. David.
- We look forward to investigating these combination therapies and their potential to improve the treatment of prostate cancer."
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
- Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018).
Retrieved on:
Wednesday, November 25, 2020
HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
Key Points:
- HOUSTON and VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference.
- The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com .
- A replay of the presentations will be available on the Company's website for 90 days.
- A Clinical Trial Application was filed with Health Canada in April 2020 and authorization was received June 3rd, 2020.
Retrieved on:
Tuesday, November 10, 2020
The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com .
Key Points:
- The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com .
- A replay of the presentations will be available on the Company's website for 90 days.
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer in patients whose disease is progressing despite treatment with current therapies.
- A Clinical Trial Application was filed with Health Canada in April 2020 and authorization was received June 3rd, 2020.
Retrieved on:
Monday, September 21, 2020
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX)(TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Key Points:
- HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX)(TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Dr. David.
- The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com .
- A replay of the presentations will be available on the Company's website for 90 days.
- A Clinical Trial Application was filed with Health Canada in April 2020 and authorization was received June 3rd, 2020.
